Procedural and Short-Term Follow-Up Outcomes of Amplatzer Amulet Occluder versus Watchman FLX Device: A Meta-Analysis

Left atrial appendage (LAA) occlusion provides effective protection against thromboembolic (TE) events in high-risk atrial fibrillation patients. Two percutaneous devices are currently available in the United States for stroke prophylaxis: the WatchmanTM device (Boston Scientific, USA) and the AmplatzerTM AmuletTM Left Atrial Appendage Occluder (Abbott, USA). The latter has recently received Food and Drug Administration approval as a result of the findings of the Amulet IDE randomized trial (1), which showed superiority for LAA occlusion (lower rates of leaks>5mm) based on a comparison between the second generation AmplatzerTM plug, namely the AmuletTM Occluder, and the old generation WatchmanTM 2.5.

Source: Heart Rhythm - February 11, 2022 Category: Cardiology Authors: Domenico G. Della Rocca, Michele Magnocavallo, Carola Gianni, Sanghamitra Mohanty, Veronica N. Natale, Amin Al-Ahmad, Carlo Lavalle, Rodney P. Horton, Luigi Di Biase, Andrea Natale Source Type: research